ArticleCurrent microbiology2025
Comprehensive Molecular Profiling of AcrAB-TolC Efflux Pump Genes in Salmonella typhi Isolates from Typhoid Infected Patients.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Azithromycin Resistance in Salmonella Typhi and Paratyphi Across South Asia: A Systematic Review and Meta-Analysis.Open forum infectious diseases · 2026Review
- Molecular Insights into the MdtABC Efflux Pump Genes in ClinicalCurrent pharmaceutical design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella typhi is a facultative anaerobic, rod-shaped, Gram-negative bacterium that causes typhoid fever, a potentially fatal systemic infection. This study aimed to characterize antibiotic susceptibility patterns, mutations at the molecular level, and efflux pump genes in clinical isolates. In this study, blood samples (n = 2950) were collected from suspected typhoid-infected patients, and 380 (12.88%) bacterial isolates were found, comprising 144 (37.89%) Gram-positive and 236 (62.10%) Gram-negative bacteria. S. typhi was identified in 95 isolates (25%), corresponding to an overall prevalence of 3.22%. Biochemical identification was performed by Analytical Profile Index (API) 20-E strips, and molecular identification was done by partial 16S rRNA gene using PCR. The S. typhi isolates were categorized into multidrug-resistant (MDR), 13 (13.68%), and extensively drug-resistant (XDR), 82 (86.31%), and their resistance patterns were recorded. Ampicillin (98.94%) and chloramphenicol (93.68%) showed the highest antibiotic resistance profiles, while azithromycin and meropenem exhibited no resistance. Numerous mutations were found in acrA, acrB, and tolC genes after sequencing; TolC (MDR) showed the highest score (16 points), and AcrB (MDR) displayed the lowest score (9 points). I-Mutant 2.0 was used to assess mutations and calculate the reliability index (RI), whereas trRosetta and Discovery Studio were used to predict and refine 3D protein models. Consensus sequences of the selected genes were analyzed to construct phylogenetic trees illustrating evolutionary relationships with other Salmonella enterica serovars. The study emphasizes the concerning multidrug resistance of S. typhi isolates as well as notable mutations (genetic changes) that may affect efflux pump activity and contribute to resistance.
Indexed as
Identifiers
40844743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.